These DC‐expressed genes (Figure 2C) are known to dampen cytotoxic T cell activity,[20] suggesting their potential viability as alternative immune checkpoint targets over CTLA4 or PD‐L1/PD‐1 for HCC immunotherapy. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.